Government-Owned Inventions; Availability for Licensing, 11560-11562 [2012-4376]
Download as PDF
<![CDATA[
11560
Federal Register / Vol. 77, No. 38 / Monday, February 27, 2012 / Notices
Outcome information to be collected
includes measures of agency-funded
research resulting in dissemination of
findings, investigator career
development, grant-funded knowledge
and products, commercial products and
drugs, laws, regulations and standards,
guidelines and recommendations,
information on patents and new drug
applications and community outreach
and public awareness relevant to
extramural research funding and
emerging areas of research. Satisfaction
information to be collected includes
measures of satisfaction with the type of
funding or program management
mechanism used, challenges and
benefits with the program support
received, and gaps in the research.
Frequency of Response: Once per
grantee, per NIEHS research portfolio.
Affected Public: Current or past NIEHS
grantees. Type of Respondents:
Principal Investigators with current or
past NIEHS research or training grants.
The annual reporting burden is as
follows: Estimated Number of
Respondents: 600; Estimated Number of
Responses per Respondent: 1; Average
Burden Hours per Response: .5 (30
minutes); and Estimated Total Annual
Burden Hours Requested: 100. The
annualized cost to respondents is
estimated at: Approximately $17. There
are no Capital Costs to report. There are
no Operating or Maintenance Costs to
report.
(Note: The following table is acceptable for
the Respondent and Burden Estimate
information, if appropriate, instead of the
text as shown above.)
Estimated
number of
respondents
Estimated
number of
responses per
respondent
Average
burden hours
per response
(min.)
Estimated total
annual burden
hours
requested
NIEHS Grantee ................................................................................................
srobinson on DSK4SPTVN1PROD with NOTICES
Type of respondents
600
1
30
100
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: Desk Officer for NIH. To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact
Dr. Kristianna Pettibone, Evaluator,
Program Analysis Branch, NIEHS, NIH,
530 Davis Dr., Room 3055, Morrisville,
NC 20560, or call non-toll-free number
919–541–7752 or email your request,
including your address to:
pettibonekg@niehs.nih.gov.
Comments Due Date: Comments
regarding this information collection are
VerDate Mar<15>2010
18:10 Feb 24, 2012
Jkt 226001
best assured of having their full effect if
received within 30-days of the date of
this publication.
Dated: February 16, 2012.
Joellen M. Austin,
Associate Director for Management, NIEHS,
National Institutes of Health.
[FR Doc. 2012–4543 Filed 2–24–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
ADDRESSES:
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
be required to receive copies of the
patent applications.
Model Cell Lines With and Without
AKT1 Mutations Derived From Proteus
Syndrome Patients
Description of Technology: The
Proteus syndrome is a congenital
disorder characterized by patchy
overgrowth and hyperplasia (cell
proliferation) of multiple tissues and
organs, along with susceptibility to
developing tumors. It is a rare disorder,
with incidence of less than one case per
million, caused by a somatic mutation.
It is also a mosaic disorder, that is one
in which cells of the same person have
different genetic content from one
another. The NHGRI inventors have
generated cell lines from patients with
Proteus syndrome and discovered that a
somatic activating mutation in the
serine-threonine kinase AKT1 is
associated with Proteus syndrome.
AKT1 is an oncogene and an enzyme
known to mediate cell proliferation and
apoptosis (programmed cell death
process) and has been a target for anticancer therapies. A number of singlecell lines with the AKT1 mutation
showing increased AKT1
phosphorylation and their matched
controls without the mutation have been
generated. The cell lines can be used to
screen therapeutic targets for AKT1, for
study design, as models of Proteus
syndrome and early stages of cancerous
conditions.
Potential Commercial Applications
• Cell lines generated from patients
with Proteus syndrome.
• Obtained a number of single-cell
lines with the AKT1 mutation and their
matched controls without the mutation.
E:\FR\FM\27FEN1.SGM
27FEN1
Federal Register / Vol. 77, No. 38 / Monday, February 27, 2012 / Notices
• Cell lines with the mutation
showed increased AKT1
phosphorylation for activating mutation.
Competitive Advantages
• Screening of potential therapeutics
that target AKT1.
• Cell lines have well-matched
controls for rigorous study design.
• Serves as model cell lines of
Proteus syndrome and early stages of
cancerous conditions.
Development Stage
• Prototype.
• Clinical.
• In vivo data available (human).
Inventors: Leslie G. Biesecker and
Marjorie J. Lindhurst (NHGRI).
Publication: Lindhurst MJ, et al. A
mosaic activating mutation in AKT1
associated with the Proteus syndrome.
N Engl J Med. 2011 Aug 18;365(7):611–
619. [PMID 21793738].
Intellectual Property: HHS Reference
No. E–033–2012/0 — Research Tool.
Patent protection is not being pursued
for this technology.
Licensing Contact: Whitney Hastings,
Ph.D.; 301–451–7337;
hastingw@mail.nih.gov
Non-toxic Compounds That Inhibit the
Formation and Spreading of Tumors
Description of Technology: Available
for licensing are novel
pyrrolopyrimidine compounds that
disrupt the assembly of the
perinucleolar compartment (PNC), a
sub-nuclear structure highly prevalent
in metastatic tumors. These notable
compounds act without overt
cytotoxicity.
The presence of the PNC positively
correlates with metastatic capacity,
making it a potential marker for cancer
development and prognosis. These
compounds could also serve as useful
tools to elucidate the biology driving the
formation and maintenance of the PNC,
and unravel its association with
metastasis.
Potential Commercial Applications
• Use in the therapeutic intervention
of metastasis in cancer.
• Use as tools to elucidate the biology
of the PNC.
srobinson on DSK4SPTVN1PROD with NOTICES
Competitive Advantages
• No existing FDA-approved
treatment for the clinical management of
metastasis.
• Target is specific to metastatic
tumors.
• Compounds are not toxic.
• Broadly acting across all metastatic
cancers.
VerDate Mar<15>2010
18:10 Feb 24, 2012
Jkt 226001
11561
Development Stage
Publications
• Early-stage.
• In vitro data available.
Inventors: Samarjit Patnaik et al.
(NCATS).
Intellectual Property: HHS Reference
No. E–276–2011/0 — U.S. Provisional
Application No. 61/576,780 filed 16 Dec
2011.
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560;
mccuepat@mail.nih.gov.
Collaborative Research Opportunity:
The National Center for Advancing
Translational Sciences is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize this technology. For
collaboration opportunities, please
contact Lili M. Portilla, MPA at 301–
217–2589 or Lilip@nih.gov.
1. Cai L, et al. Synthesis and
structure-affinity relationships of new 4(6-iodo-H-imidazo[1,2-a]pyridin-2-yl)-Ndimethylbenzeneamine derivatives as
ligands for human beta-amyloid
plaques. J Med Chem. 2007 Sep
20;50(19):4746–4758. [PMID 17722900].
2. Cai L, et al. Synthesis and
evaluation of N-methyl and S-methyl
11C-labeled 6-methylthio-2-(4’-N,Ndimethylamino)phenylimidazo[1,2a]pyridines as radioligands for imaging
beta-amyloid plaques in Alzheimer’s
disease. J Med Chem. 2008 Jan
10;51(1):148–158. [PMID 18078311].
Intellectual Property: HHS Reference
No. E–225–2011/0—U.S. Provisional
Application No. 61/535,569 filed 16 Sep
2011.
Related Technology: HHS Reference
No. E–156–2006/0—U.S. Patent
Application No. 12/293,340 filed 17 Sep
2008.
Licensing Contact: Tedd Fenn, J.D.;
301–435–5031; Tedd.Fenn@nih.gov.
Collaborative Research Opportunity:
The National Institute of Mental Health
(NIMH) is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize Beta-amyloid Imaging
Agents. For collaboration opportunities,
please contact Suzanne L. Winfield,
Ph.D. at winfiels@intra.nimh.nih.gov or
301–402–4324.
Novel Radio-Labeled Agents for
Imaging Alzheimer’s DiseaseAssociated Amyloid
Description of Technology: This
technology introduces novel radiolabeled agents for imaging amyloid
deposits in the brains of Alzheimer’s
Disease patients. These are small
molecule, radio-ligand compounds that
are analogs of benzo[d]thiazole. They
are highly specific to amyloid, have low
background noise, do not undergo rapid
defluoridation and do not produce
residual radioactivity in the brain. In
addition, the compounds are stable and
may be readily synthesized from
commercially available starting
materials. These compounds may be
used in many noninvasive imaging
techniques including: magnetic
resonance spectroscopy (MRS) or
imaging (MRI), or positron emission
tomography (PET) or single-photon
emission computed tomography
(SPECT) to measure amyloid. Noninvasive detection of Alzheimer’s
disease-associated amyloid plaques in
the brain would be valuable for early
diagnosis, monitoring, and for clinical
development of therapeutic drugs.
Potential Commercial Applications:
Imaging agents for use in magnetic
resonance spectroscopy (MRS), or
imaging (MRI), positron emission
tomography (PET) or single-photon
emission computed tomography
(SPECT).
Competitive Advantages: Highly
specificity to amyloid, low background,
do not undergo rapid defluoridation and
do not produce residual radioactivity in
the brain.
Development Stage: Early-stage.
Inventors: Lisheng Cai and Victor W.
Pike (NIMH).
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
A New Class of Broad-Spectrum
Antibiotics: Naturally-Occurring
Chrysophaetins and Their Analogues
Description of Technology: This
invention, offered for licensing and
commercial development, relates to a
new class of naturally occurring
antimicrobial compounds called
Chrysophaetins, and to their synthetic
analogues. Isolated from an alga species,
the mechanism of action of these
compounds is through the inhibition of
bacterial cytoskeletal protein FtsZ, an
enzyme necessary for the replication of
bacteria. FtsZ is responsible for Z-ring
assembly in bacteria, which leads to
bacterial cell division. Highly conserved
among all bacteria, FtsZ is a very
attractive antimicrobial target.
The chrysophaetin exhibits
antimicrobial activity against drug
resistant bacteria, methicillin-resistant
Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococcus
faecalis (VRE), as well as other drug
susceptible strains. The general
structure of the natural compound is
shown below:
E:\FR\FM\27FEN1.SGM
27FEN1
11562
Federal Register / Vol. 77, No. 38 / Monday, February 27, 2012 / Notices
Dated: February 21, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2012–4376 Filed 2–24–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
• Therapeutic potential for treating
general and drug-resistant bacterial
infections in clinical and veterinary
populations.
• Antiseptics in hospital settings.
Competitive Advantages
• Effective for commonly occurring
drug-resistant infections MRSA and
VRE.
• Broad spectrum of efficacy because
mechanism of action is against the
bacterial protein FtsZ, which has similar
structure in all bacteria.
• Potential for additive efficacy when
combined with other antibiotics due to
distinct mechanism of action.
• Other drugs with similar structure
and antibacterial properties can be
synthesized using the chemical
structure template shown above.
srobinson on DSK4SPTVN1PROD with NOTICES
Development Stage
• Early-stage.
• In vitro data available.
Inventors: Carole A Bewley, et al.
(NIDDK).
Publication: Plaza A, et al.
Chrysophaentins A–H, antibacterial
bisdiarylbutene macrocycles that inhibit
the bacterial cell division protein FtsZ.
J Am Chem Soc. 2010 Jul
7;132(26):9069–9077. [PMID 20536175].
Intellectual Property: HHS Reference
No. E–116–2010/0—PCT Application
No. PCT/US2011/026200 filed 25 Feb
2011, which published as WO 2011/
106630 on 01 Sep 2011.
Licensing Contact: John Stansberry,
Ph.D.; 301–435–5236;
stansbej@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Diseases,
Laboratory of Bioorganic Chemistry, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize the
chrysophaentin antibiotics. Please
contact Marguerite J. Miller at 301–451–
3636 or millermarg@niddk.nih.gov for
more information.
VerDate Mar<15>2010
19:27 Feb 24, 2012
Jkt 226001
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to Section 10(d) of the
Federal Advisory Committee Act, as
Amended (5 U.S.C. App.), Notice Is
Hereby Given of the Following
Meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel Review of Minority Biomedical
Research Support Genetics Applications.
Date: March 19–20, 2012.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency—Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Saraswathy Seetharam,
Ph.D., Scientific Review Officer, Office of
Scientific Review, National Institute of
General Medical Sciences, National Institutes
of Health, 45 Center Drive, Room 3An12C,
Bethesda, MD 20892, 301–594–2763,
seetharams@nigms.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
National Institutes of Health
National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel P30
Review
Date: March 28, 2012.
Time: 12:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6120
Executive Blvd., Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Christine A. Livingston,
Ph.D. Scientific Review Officer, Division of
Extramural Activities, National Institutes of
Health/NIDCD, 6120 Executive Blvd.—MSC
7180, Bethesda, MD 20892, (301) 496–8683,
livingsc@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcd.nih.gov/about/groups/sep/,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: February 21, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–4535 Filed 2–24–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: February 21, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2012–4526 Filed 2–24–12; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
BILLING CODE 4140–01–P
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
National Institute of General Medical
Sciences; Notice of Closed Meeting
E:\FR\FM\27FEN1.SGM
27FEN1
EN27FE12.009</GPH>
Potential Commercial Applications
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
]]>Agencies
[Federal Register Volume 77, Number 38 (Monday, February 27, 2012)]
[Notices]
[Pages 11560-11562]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-4376]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Model Cell Lines With and Without AKT1 Mutations Derived From Proteus
Syndrome Patients
Description of Technology: The Proteus syndrome is a congenital
disorder characterized by patchy overgrowth and hyperplasia (cell
proliferation) of multiple tissues and organs, along with
susceptibility to developing tumors. It is a rare disorder, with
incidence of less than one case per million, caused by a somatic
mutation. It is also a mosaic disorder, that is one in which cells of
the same person have different genetic content from one another. The
NHGRI inventors have generated cell lines from patients with Proteus
syndrome and discovered that a somatic activating mutation in the
serine-threonine kinase AKT1 is associated with Proteus syndrome. AKT1
is an oncogene and an enzyme known to mediate cell proliferation and
apoptosis (programmed cell death process) and has been a target for
anti-cancer therapies. A number of single-cell lines with the AKT1
mutation showing increased AKT1 phosphorylation and their matched
controls without the mutation have been generated. The cell lines can
be used to screen therapeutic targets for AKT1, for study design, as
models of Proteus syndrome and early stages of cancerous conditions.
Potential Commercial Applications
Cell lines generated from patients with Proteus syndrome.
Obtained a number of single-cell lines with the AKT1
mutation and their matched controls without the mutation.
[[Page 11561]]
Cell lines with the mutation showed increased AKT1
phosphorylation for activating mutation.
Competitive Advantages
Screening of potential therapeutics that target AKT1.
Cell lines have well-matched controls for rigorous study
design.
Serves as model cell lines of Proteus syndrome and early
stages of cancerous conditions.
Development Stage
Prototype.
Clinical.
In vivo data available (human).
Inventors: Leslie G. Biesecker and Marjorie J. Lindhurst (NHGRI).
Publication: Lindhurst MJ, et al. A mosaic activating mutation in
AKT1 associated with the Proteus syndrome. N Engl J Med. 2011 Aug
18;365(7):611-619. [PMID 21793738].
Intellectual Property: HHS Reference No. E-033-2012/0 -- Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Whitney Hastings, Ph.D.; 301-451-7337;
hastingw@mail.nih.gov
Non-toxic Compounds That Inhibit the Formation and Spreading of Tumors
Description of Technology: Available for licensing are novel
pyrrolopyrimidine compounds that disrupt the assembly of the
perinucleolar compartment (PNC), a sub-nuclear structure highly
prevalent in metastatic tumors. These notable compounds act without
overt cytotoxicity.
The presence of the PNC positively correlates with metastatic
capacity, making it a potential marker for cancer development and
prognosis. These compounds could also serve as useful tools to
elucidate the biology driving the formation and maintenance of the PNC,
and unravel its association with metastasis.
Potential Commercial Applications
Use in the therapeutic intervention of metastasis in
cancer.
Use as tools to elucidate the biology of the PNC.
Competitive Advantages
No existing FDA-approved treatment for the clinical
management of metastasis.
Target is specific to metastatic tumors.
Compounds are not toxic.
Broadly acting across all metastatic cancers.
Development Stage
Early-stage.
In vitro data available.
Inventors: Samarjit Patnaik et al. (NCATS).
Intellectual Property: HHS Reference No. E-276-2011/0 -- U.S.
Provisional Application No. 61/576,780 filed 16 Dec 2011.
Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560;
mccuepat@mail.nih.gov.
Collaborative Research Opportunity: The National Center for
Advancing Translational Sciences is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact Lili M. Portilla, MPA at 301-217-2589 or
Lilip@nih.gov.
Novel Radio-Labeled Agents for Imaging Alzheimer's Disease-Associated
Amyloid
Description of Technology: This technology introduces novel radio-
labeled agents for imaging amyloid deposits in the brains of
Alzheimer's Disease patients. These are small molecule, radio-ligand
compounds that are analogs of benzo[d]thiazole. They are highly
specific to amyloid, have low background noise, do not undergo rapid
defluoridation and do not produce residual radioactivity in the brain.
In addition, the compounds are stable and may be readily synthesized
from commercially available starting materials. These compounds may be
used in many noninvasive imaging techniques including: magnetic
resonance spectroscopy (MRS) or imaging (MRI), or positron emission
tomography (PET) or single-photon emission computed tomography (SPECT)
to measure amyloid. Non-invasive detection of Alzheimer's disease-
associated amyloid plaques in the brain would be valuable for early
diagnosis, monitoring, and for clinical development of therapeutic
drugs.
Potential Commercial Applications: Imaging agents for use in
magnetic resonance spectroscopy (MRS), or imaging (MRI), positron
emission tomography (PET) or single-photon emission computed tomography
(SPECT).
Competitive Advantages: Highly specificity to amyloid, low
background, do not undergo rapid defluoridation and do not produce
residual radioactivity in the brain.
Development Stage: Early-stage.
Inventors: Lisheng Cai and Victor W. Pike (NIMH).
Publications
1. Cai L, et al. Synthesis and structure-affinity relationships of
new 4-(6-iodo-H-imidazo[1,2-a]pyridin-2-yl)-N-dimethylbenzeneamine
derivatives as ligands for human beta-amyloid plaques. J Med Chem. 2007
Sep 20;50(19):4746-4758. [PMID 17722900].
2. Cai L, et al. Synthesis and evaluation of N-methyl and S-methyl
11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-
a]pyridines as radioligands for imaging beta-amyloid plaques in
Alzheimer's disease. J Med Chem. 2008 Jan 10;51(1):148-158. [PMID
18078311].
Intellectual Property: HHS Reference No. E-225-2011/0--U.S.
Provisional Application No. 61/535,569 filed 16 Sep 2011.
Related Technology: HHS Reference No. E-156-2006/0--U.S. Patent
Application No. 12/293,340 filed 17 Sep 2008.
Licensing Contact: Tedd Fenn, J.D.; 301-435-5031;
Tedd.Fenn@nih.gov.
Collaborative Research Opportunity: The National Institute of
Mental Health (NIMH) is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize Beta-amyloid Imaging Agents. For
collaboration opportunities, please contact Suzanne L. Winfield, Ph.D.
at winfiels@intra.nimh.nih.gov or 301-402-4324.
A New Class of Broad-Spectrum Antibiotics: Naturally-Occurring
Chrysophaetins and Their Analogues
Description of Technology: This invention, offered for licensing
and commercial development, relates to a new class of naturally
occurring antimicrobial compounds called Chrysophaetins, and to their
synthetic analogues. Isolated from an alga species, the mechanism of
action of these compounds is through the inhibition of bacterial
cytoskeletal protein FtsZ, an enzyme necessary for the replication of
bacteria. FtsZ is responsible for Z-ring assembly in bacteria, which
leads to bacterial cell division. Highly conserved among all bacteria,
FtsZ is a very attractive antimicrobial target.
The chrysophaetin exhibits antimicrobial activity against drug
resistant bacteria, methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant Enterococcus faecalis (VRE), as well as other
drug susceptible strains. The general structure of the natural compound
is shown below:
[[Page 11562]]
[GRAPHIC] [TIFF OMITTED] TN27FE12.009
Potential Commercial Applications
Therapeutic potential for treating general and drug-
resistant bacterial infections in clinical and veterinary populations.
Antiseptics in hospital settings.
Competitive Advantages
Effective for commonly occurring drug-resistant infections
MRSA and VRE.
Broad spectrum of efficacy because mechanism of action is
against the bacterial protein FtsZ, which has similar structure in all
bacteria.
Potential for additive efficacy when combined with other
antibiotics due to distinct mechanism of action.
Other drugs with similar structure and antibacterial
properties can be synthesized using the chemical structure template
shown above.
Development Stage
Early-stage.
In vitro data available.
Inventors: Carole A Bewley, et al. (NIDDK).
Publication: Plaza A, et al. Chrysophaentins A-H, antibacterial
bisdiarylbutene macrocycles that inhibit the bacterial cell division
protein FtsZ. J Am Chem Soc. 2010 Jul 7;132(26):9069-9077. [PMID
20536175].
Intellectual Property: HHS Reference No. E-116-2010/0--PCT
Application No. PCT/US2011/026200 filed 25 Feb 2011, which published as
WO 2011/106630 on 01 Sep 2011.
Licensing Contact: John Stansberry, Ph.D.; 301-435-5236;
stansbej@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic
Chemistry, is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize the chrysophaentin antibiotics. Please contact Marguerite
J. Miller at 301-451-3636 or millermarg@niddk.nih.gov for more
information.
Dated: February 21, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-4376 Filed 2-24-12; 8:45 am]
BILLING CODE 4140-01-P
